Takeda Completes Acquisition of Shire, Becoming a Global, Values-Based, R&D-Driven Biopharmaceutical Leader
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (Takeda) today announced the completion of its acquisition of Shire plc (Shire), becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan.
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”)
today announced the completion of its acquisition of Shire plc
(“Shire”), becoming a global, values-based, R&D-driven biopharmaceutical
leader headquartered in Japan.
Takeda now has an attractive, expanded geographic footprint and leading
position in Japan and the U.S., bringing its highly-innovative medicines
to approximately 80 countries/regions with dedicated employees
worldwide. Takeda’s R&D efforts are focused on its four therapeutic
areas of Oncology, Gastroenterology (GI), Neuroscience and Rare
Diseases, with targeted R&D investment also committed to Plasma-Derived
Therapies (PDT) and Vaccines. Takeda's strengthened, highly innovative
R&D engine enables the company to have a more global, robust and
modality-diverse pipeline as well as to focus on breakthrough
innovation. The combined annual revenue of the company, exceeding $30
billion USD, is mainly derived from the key business areas of Oncology,
GI, Neuroscience, Rare Diseases and PDT.
“We are delighted that the acquisition was approved by an overwhelming
majority of our shareholders at Takeda's extraordinary general meeting
on December 5th, 2018. We are also pleased to have completed
the acquisition several months earlier than expected, which was enabled
through the hard work of our respective organizations and the smooth
receipt of regulatory clearances,” said Christophe Weber, President and
Chief Executive Officer of Takeda. “We appreciate the support of our
employees, partners and shareholders throughout the process. This marks
a significant moment in Takeda’s history and is an exciting step forward
as we accelerate our transformation journey to deliver highly-innovative
medicines to patients around the world with expanded scale and
geographical footprint.”
Weber continued, “The execution of our integration begins today, and we
are confident in our ability to execute a smooth integration under the
leadership of our experienced and diverse Takeda Executive Team with a
strong track record. The Operating Model we established in September
last year has set a clear framework for our integration plans, and we
have a highly skilled and dedicated integration team leading the
process.”
In order to fund the acquisition, Takeda has secured permanent financing
with highly competitive rates, resulting in an overall blended interest
rate for Takeda's total debt of approximately 2.3%. The company is
confident that it will retain its investment grade credit rating and
return to a net debt to EBITDA ratio of 2.0x or less within three to
five years following completion.
Weber will present at the J.P. Morgan Healthcare Conference at 3:30 p.m.
PST on January 8, 2019.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) is a
global, values-based, R&D-driven biopharmaceutical leader headquartered
in Japan, committed to bringing Better Health and a Brighter Future to
patients by translating science into highly-innovative medicines. Takeda
focuses its R&D efforts on four therapeutic areas: Oncology,
Gastroenterology (GI), Neuroscience and Rare Diseases. We also make
targeted R&D investments in Plasma-Derived Therapies and Vaccines. We
are focusing on developing highly innovative medicines that contribute
to making a difference in people's lives by advancing the frontier of
new treatment options and leveraging our enhanced collaborative R&D
engine and capabilities to create a robust, modality-diverse pipeline.
Our employees are committed to improving quality of life for patients
and to working with our partners in health care in approximately 80
countries and regions.
For more information, visit https://www.takeda.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005584/en/